Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
The purpose of the study is to assess the effect of Sunitinib on tumor vascularization and necrosis in patients with metastatic renal cell cancer.
Renal Cell Cancer
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Pilot Study on the Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma|
|Study Start Date:||October 2008|
|Study Completion Date:||May 2010|
Sutent is an angiogenesis inhibitor used in the treatment of renal cell cancer. Very often tumor necrosis is seen after the start of the treatment. It is unknown after how many days this effect starts. In patients with renal cell cancer with metastases, who will be treated with Sutent, 3 MRIs will be made. Kep, R2*, b-coefficient (perfusion, hypoxia, blood volume and necrosis) will be measured.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00509704
|UMC St Radboud|
|Principal Investigator:||C.M.L. van Herpen, MD, PhD||UMC St Radboud|